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Aim To determine if there are correlations between joint 
and fascial chronic graft-vs-host disease (cGVHD) with clin-
ical findings, laboratory parameters, and measures of func-
tional capacity.
Methods 29 patients were diagnosed with cGVHD based 
on National Institutes of Health (NIH) Consensus Criteria at 
the University Hospital Centre Zagreb from October 2013 
to October 2015. Physical examination, including func-
tional measures such as 2-minute walk test and hand grip 
strength, as well as laboratory tests were performed. The 
relationship between these evaluations and the severity of 
joint and fascial cGVHD was tested by logistical regression 
analysis.
Results 12 of 29 patients (41.3%) had joint and fascial 
cGVHD diagnosed according to NIH Consensus Criteria. 
There was a significant positive correlation of joint and 
fascial cGVHD and skin cGVHD (P < 0.001), serum C3 com-
plement level (P = 0.045), and leukocytes (P = 0.032). There 
was a significant negative correlation between 2-minute 
walk test (P = 0.016), percentage of cytotoxic T cells CD3+/
CD8+ (P = 0.022), serum albumin (P = 0.047), and Karnofsky 
score (P < 0.001). Binary logistic regression model found 
that a significant predictor for joint and fascial cGVHD was 
cGVHD skin involvement (odds ratio, 7.79; 95 confidence 
interval 1.87-32.56; P = 0.005).
Conclusion Joint and fascial cGVHD manifestations corre-
lated with multiple laboratory measurements, clinical fea-
tures, and cGVHD skin involvement, which was a signifi-
cant predictor for joint and fascial cGVHD.
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Chronic graft-vs-host disease (cGVHD) is a major late com-
plication of allogeneic hematopoietic stem cell transplan-
tation (alloHSCT), typically occurring within three years 
post-transplant and affecting approximately 30%-50% of 
allogeneic transplant survivors (1-5). Its effects can be dev-
astating, including high morbidity and disability, and it is 
the leading cause of non-relapse mortality (5). cGVHD is 
distinct from acute GVHD, which manifests earlier in the 
post-transplant course, with characteristic skin and gastro-
intestinal symptoms, and affects multiple organ systems 
including the joints and fascia, skin, eyes, mouth, lung, liver, 
gastrointestinal tract, and genital tract in female patients 
(5). cGVHD occurs because the recipient’s immune system 
recognizes the donor’s tissues as foreign, causing inflam-
mation and fibrosis in highly mitotic areas (6). Potential risk 
factors for cGVHD development include major human leu-
kocyte antigen (HLA) allele mismatch between donor and 
recipient, T-cell replete graft, the use of peripheral blood 
as the stem cell source, donor lymphocyte infusion, older 
recipient age, the use of a female donor for a male recip-
ient, and prior acute GVHD (7). Although cGVHD can in-
volve many organ systems, joint and fascial involvement 
is relatively common and can cause significant function-
al impairment (8). Caused by inflammation of the fascia, 
including an eosinophilic component, it may manifest as 
joint stiffness, erythema, edema, restricted range of mo-
tion (ROM), arthralgia, and rarely arthritis or synovitis (5,6,8). 
Joint and fascial manifestations can be clinically detectable 
when inflammation and fibrosis arise in deep tissues (deep 
sclerosis/fasciitis) or skin overlying joints (superficial scle-
rosis) (5,6,8). Widespread sclerosis may result in joint con-
tractures and severe limitation of function, and common 
sites of involvement include the hands/wrists, shoulders, 
elbows, and ankles (6,8).
Despite the potential for functional impairment in persons 
with joint and fascial cGVHD, little is known about the cor-
relation of joint and fascial cGVHD with other clinical and 
laboratory manifestations of cGVHD, and about the over-
all physical performance in persons with joint and fascial 
cGVHD (9). Some studies have previously looked at overall 
physical function in persons with cGVHD, which includes 
joint involvement (6,10), or attempted to predict joint and 
fascial cGVHD onset with laboratory data (11), but no study 
to date has determined the correlations between labo-
ratory data, functional impairment, and joint and fascial 
cGVHD. In this study, we investigated if there was a cor-
relation between laboratory data, including markers of 
inflammation and of immune system reconstitution after 
alloHSCT, clinical and physical manifestations of cGVHD, in-
cluding those that affect other organ systems, and overall 
physical function in persons with joint and fascial cGVHD. 
Knowledge about these correlations may lead to a better 
understanding of the pathophysiology, earlier detection of 
the disease, and improved diagnosis and management.
PaTiENTS aND mEThoDS
Data for this descriptive follow-up study were gathered 
from 32 patients who were suspected of having developed 
cGVHD after alloHSCT. This study is a part of a larger pro-
tocol entitled “Clinical And Biological Factors Determining 
Severity and Activity of Chronic Graft-versus-Host Disease 
after Allogeneic Hematopoietic Stem Cell Transplantation“ 
which studied the natural history of cGVHD and evaluated 
patients according to the NIH Consensus Criteria (5). The 
protocol involved the collection of comprehensive demo-
graphic, historical, laboratory, clinical, histopathologic, and 
imaging data. The research was approved by the Ethics 
Committee of University Hospital Centre Zagreb and Uni-
versity of Zagreb School of Medicine and all participants 
or their guardians gave written informed consent in accor-
dance with the Declaration of Helsinki.
Patients were enrolled in this study from October 2013 
to October 2015 and evaluated at the University Hospital 
Centre Zagreb. For each patient NIH cGVHD (0-3) organ-
specific scores for 8 organs (skin, eye, mouth, liver, gastro-
intestinal tract, lungs, joint/fascia, and female genital tract) 
were assigned by specialists for a specific area after exam-
ining every patient. NIH global score was graded as “mild” 
(1-2 organs with scores 1), “moderate” (more than 2 organs 
with score 1, any score 2, or lung score 1), or “severe” (any 
score of 3 or lung score 2) (5). Patients’ performance sta-
tus was measured with Karnofsky score, a decile scale that 
classifies patients based on functional impairment (12).
Joint involvement was determined in accordance with 
written testing procedures and included a measurement 
of upper and lower body range of motion (ROM), domi-
nant and non-dominant hand grip strength (HGS), and 
walking assessment (13-18). All measures were obtained 
in a single patient visit. To assess the severity of joint and 
fascia involvement, the NIH 0-3 point joint and fascia scale 
that scores a composite of tightness, ROM and activities of 
daily living (ADL) was used (Table 1) (5). Joint and fascial 
cGVHD was diagnosed if the patient had NIH joint and 
fascia score ≥1 (5). Active assisted ROM measurements 
were performed in the supine position using a standard 
goniometer, and all measures were compared with 
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predicted values for each individual joint established by 
the American Academy of Orthopaedic Surgeons (13). Pa-
tients were examined thoroughly by a rehabilitation medi-
cine specialist and detailed medical history was taken to 
exclude any history of a previous trauma, infection, neuro-
muscular disorder, or any type of connective tissue disease 
that could affect patients’ ROM independent of cGVHD. No 
patients had these conditions, which would have excluded 
them from the study group. To determine the severity of 
joint and fascia involvement, the joint with the greatest re-
striction in ROM was used in the analysis for each patient. 
The Photographic Range of Motion (P-ROM) scale was also 
used in this study (19). P-ROM scale captures ROM sepa-
rately for shoulders, elbows, wrists/fingers, and ankles in a 
series of images. P-ROM total score is the sum of scores 
in all 4 joints with a maximum of 25 points. Lower scores 
indicate more limited ROM. P-ROM scale only considers 
ROM limitations and does not include tightness or ADLs, 
which is different from the NIH joint/fascia scale (5,19). The 
NIH joint/fascia scale and P-ROM scale are validated scales 
for assessing joint and fascial manifestations (5,6,19). NIH 
joint/fascia scale was developed to evaluate joint and fas-
cial cGVHD manifestations for baseline and cross-sectional 
studies, but longitudinal changes may also be evaluated 
with this scale (5,6). P-ROM scale has been validated to be 
used in longitudinal studies and was more sensitive to per-
ceived joint worsening among cGVHD joint/fascia mani-
festations than the NIH joint/fascia scale (6).
Patient walking assessment was performed by a 2-minute 
walk test, which was used instead of the 6-minute walk test 
(20,21). This was done because 2-minute walk test is a part 
of the NIH Consensus Criteria (15), and numerous studies 
support the construct validity and responsiveness of the 
2-minute walk test as a measure of functional capacity 
in other chronically ill populations (15,20,21). In 2-min-
ute walk test the patient is instructed to walk a 15-m 
course (7.5 m each direction) with 180 degree turns at 
each end, and the total distance covered in two minutes is 
recorded (16). HGS for hand strength evaluation was mea-
sured for dominant and non-dominant hand (18), and was 
performed three times for each hand with small intervals 
between using a hand hydraulic dynamometer (18) (Jamar 
Hydraulic Hand Dynamometer; Sammons Preston Rolyan, 
Chicago, IL, USA).
Laboratory studies were performed at the time of clinical 
evaluation and blood samples were submitted to routine 
laboratory analysis at the Department of Laboratory Medi-
cine at the University Hospital Centre Zagreb. Laboratory 
tests were ordered to identify which laboratory inflamma-
tion markers are associated with joint and fascial cGVHD 
involvement. Previous studies identified a number of labo-
ratory indicators of inflammation (C-reactive protein, white 
blood count, absolute neutrophil count, platelets, and al-
bumin) that may be affected in patients with moderate 
or severe cGVHD compared with non-cGVHD transplant-
ed patients (9). Some studies have proposed eosinophilia, 
CD3 T-cell dose in the graft, and positive antinuclear anti-
bodies (ANAs) as markers of sclerotic-type chronic GVHD 
(ScGVHD) (22,23), while other have proposed elevated C3 
complement and higher platelet count (11). This suggests 
on-going tissue inflammation in this patient population, 
potentially evaluated with these laboratory measurements 
(9,11,22,23).
Statistical analysis
Categorical data are presented with absolute (N) and rel-
ative (%) frequencies and compared using Fisher exact 
test or Fisher-Freeman-Halton exact test of independence 
when the contingency table is larger than 2 × 2, and nu-
merical data are presented with median and interquartile 
range values and compared using Mann-Whitney U test. 
The normality of distribution was tested using Kolmogo-
rov-Smirnov test. Factors potentially associated with joint 
and fascial cGVHD were first screened as follows: Spear-
man rank correlation was used to determine the correla-
tion between continuous variables and Kendall tau to de-
termine the correlation between nominal variables and 
joint and fascial cGVHD. Correlations were interpreted as 
follows: rho >0.6 as a strong correlation; 0.3<rho <0.6, as a 
moderately strong correlation, and rho <0.3 as a weak cor-
relation. Binary logistic regression was used to determine 
which organ involvement was the most predictive factor 
for the development of joint and fascial cGVHD. P values 
<0.050 were considered statistically significant. Data were 
TabLE 1. NIH joint/fascia scale for cGVHD*
Nih joint/fascia scale (range, 0-3)
0: No symptoms
1: Mild tightness of arms or legs, normal or mild decreased ROM 
AND not affecting ADL
2: Tightness of arms or legs OR joint contractures, erythema 
thought due to fasciitis, moderate decrease ROM AND mild to 
moderate limitation of ADL
3: Contracture WITH significant decrease of ROM AND signifi-
cant limitation of ADL (unable to tie shoes, button shirts, dress 
self-etc.)
*aDL – activities of daily living; cGVhD – chronic graft-vs-host disease; 
Nih – National institutes of health; Rom – range of motion.
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analyzed using StatsDirect Ltd StatsDirect statistical soft-
ware (http://www.statsdirect.com).
RESuLTS
Patient demographic and clinical history
The study included 32 patients suspected of having devel-
oped cGVHD after alloHSCT. 29 patients (28 adult, 1 child) 
met the criteria for the cGVHD diagnosis according to the 
NIH cGVHD Consensus Criteria, and all had at least one or-
gan involved. 3 patients were excluded from the analysis 
as the interdisciplinary panel determined that they had 
late acute GVHD or an inconclusive diagnosis of cGVHD. 
This group was smaller than the overall number of patients 
treated for cGVHD at the University Hospital Centre Zagreb 
because all patients required functional capacity measures 
(2- minute walk test and hand grip strength) and all of them 
had to be examined by a rehabilitation medicine special-
ist; this is a time-consuming process that was not available 
to every patient. Patients were not selected for this study 
based on any criteria other than availability of team mem-
bers to provide this comprehensive assessment.
The median age at enrolment for group with joint and fas-
cial manifestations was 44.5 years (interquartile range, IQR, 
26.25-56.75 years), and 33.3% patients were female (Table 2, 
Table 3). The median time from transplantation to protocol 
entry was 843 days (IQR, 343.5- 3986.5 days). The duration 
of joint and fascia score (JFS) group was 492 days (IQR, 80- 
3393.25 days) (Table 3). The most common indications for 
transplantation in JFS group were acute leukemia or myelo-
dysplastic syndrome (N = 6; 50%), chronic myelogenous leu-
kemia (N = 5; 41.7%), and aplastic anemia in a single patient 
(N = 1; 8.3%). The majority of JFS patients (N = 7, 58.3%) were 
subjected to myeloablative conditioning regimen and 5 pa-
tients (41.7%) to reduced intensity conditioning regimen. No 
patients were subjected to high-dose total body irradiation 
conditioning. The majority of patients were related to their 
donor (N = 7; 58.3%) and there were 5 (41.7%) male HSCT re-
cipients with female donors. The most common concurrent 
organ involved in the JFS group was the skin (N = 10; 83.3%), 
followed by the lungs and eyes, (N = 7; 58,3%), mouth (N = 5; 
41.7%), and others (Table 2). The majority of patients in the 
JFS group (N = 8; 66.7%) had a NIH cGVHD global score 
defined as “severe.” There were no significant differences in 
demographic and clinical characteristic between the group 
with joint and fascia manifestations and without joint and 
fascia manifestations but with other cGVHD organ system 
involvement (Table 2).
12 of 29 patients (41.3%) manifested joint and fascial cGVHD 
according to NIH Consensus Criteria. Among patients who 
had a NIH joint/fascia score ≥1, 6 had mild disease (50%), 3 
(25%) had moderate disease, and 3 (25%) had severe dis-
ease. Reduction in ROM among cGVHD patients who were 
classified as having a NIH joint/fascia score ≥1 was mostly 
present in wrists/fingers (31%), elbows (31%), ankles (28%), 
and shoulders (24%). Limitations in ROM were present in 
multiple joints for 75% of the patients, with limited ROM in 
at least one joint for patients in JFS group. The involvement 
of upper extremities was more severe (ROM movement re-
duction – 66.7%) than the involvement of lower extremi-
ties (ROM movement reduction – 25%) for JFS group. Limi-
tations in ROM were most frequently moderate to severe in 
joints according to the P-ROM score (ie, score 6-5 for shoul-
ders, 6-4 for elbows, wrists/fingers from 6-2, and score 3- 1 
for ankles). The median of P-ROM total score at enrollment 
was 22 (IQR, 18.5- 22.75) for the JFS group, and 25 (IQR, 25- 
25) for the group without joint/fascia manifestations (Ta-
ble 3). All patients with skin involvement in the JFS group 
had ROM restriction. The involvement of upper extremities 
was more severe (ROM movement reduction – 60%) than 
the involvement of lower extremities (ROM movement re-
duction – 30%) for patients with skin involvement in the 
JFS group. Patients who had erythematous skin changes 
or mild dermal sclerotic changes had mild ROM reduction, 
and were scored as mild NIH joint/fascia score with one or 
two joints affected. Patients with moderate NIH joint/ fas-
cia score all had dermal sclerotic changes and had more 
than one joint affected. Patients with deep sclerosis chang-
es (N = 3, 25%) had a severe NIH joint/fascia score and mul-
tiple joint involvement.
Clinical, functional, and laboratory parameters
Our results showed there was a significant positive cor-
relation between cGVHD skin involvement (rho = 0.712; 
P < 0.001), total NIH score (rho = 0.603; P = 0.001), number 
of organs involved with cGVHD (rho = 0.452; P = 0.014), C3 
complement component (rho = 0.405; P = 0.045), white 
blood count (rho = 0.406; P = 0.032) and NIH joint/fascia 
score. There was a significant negative correlation between 
P-ROM scale (rho = -0.989; P < 0.001), 2-minute walk test 
(rho = -0.444; P = 0.016), serum albumin value (rho = -0.402; 
P = 0.047), Karnofsky score (rho = -0.759; P <0 .001), creatine 
kinase value (rho = -0,462; P = 0.012) and NIH joint/fascia 
score. There was also a significant negative correlation 
between percentage of cytotoxic T cells CD3+/CD8+ 
(rho = -0.456; P = 0.022) and NIH joint/fascia score, 
but between cytotoxic T cells CD3+/CD8+ count 
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(rho = -0.378; P = 0.062) and NIH joint/fascia score the re-
sult approached but did not reach statistical significance 
(Table 4).
Patients with joint and fascial cGVHD more frequently had 
skin involvement than patients without joint and fascial 
cGVHD, which was also confirmed by correlation analysis 
TabLE 2. Demographic and clinical characteristic of groups with cGVhD*
Joint/fascia manifestation 
absent at enrolment 
N = 17
Joint/fascia manifestation 
present at enrolment 
N = 12 P†
Sex of patient: n (%) male 7 41.2 8 66.7 0.264
female 10 58.8 4 33.3
Main disease: n (%) ALL, AML and MDS 11 64.7 6 50.0 0.617
CML (and myeloproliferative disorders) 3 17.6 5 41.7
CLL 1 5.9 0 0.0
aplastic anemia/PNH 2 11.8 1 8.3
Conditioning regimen: n (%) myeloablative 10 58.8 7 58.3 0.999
reduced intensity 6 35.3 5 41.7
unknown 1 5.9 0 0.0
Donor relationship: n (%) related 10 58.8 7 58.3 0.999
unrelated 7 41.2 5 41.7
Sex mismatch: n (%) M/M 3 17.6 3 25.0 0.449
F/M 3 17.6 5 41.7
F/F 5 29.4 2 16.7
M/F 5 29.4 1 8.3
unknown 1 5.9 1 8.3
Stem cell source: n (%) peripheral blood 9 52.9 8 66.7 0.827
bone marrow 7 41.2 4 33.3
unknown 1 5.9 0 0.0
none 9 56.3 5 41.7
Intensity of immunosuppression 
(Sandy’s scale)
low 1 6.3 0 0.0 0.289
moderate 5 31.3 3 25.0
high 1 6.3 4 33.3
Acute GVHD: n (%) yes 14 82.4 9 75.0 0.242
no 2 11.8 3 25.0
unknown 1 5.9 0 0.0
cGVHD onset type: n (%) de novo 2 11.8 3 25.0 0.454
progressive 5 29.4 4 33.3
quiescent 10 58.8 4 33.3
unknown 0 0.0 1 8.3
cGVHD organ involvement: n (%) skin 4 23.5 10 83.3 0.576
ocular 10 58.8 7 58.3
mouth 5 29.4 5 41.7
lung 9 52.9 7 58.3
liver 5 29.4 4 33.3
GI tract 2 11.8 1 8.3
genital (women only) 5 29.4 2 16.7
NIH cGVHD global score: n (%) mild 1 5.9 0 0.0 0.352
moderate 9 52.9 4 33.3
severe 7 41.2 8 66.7
*aLL – acute lymphoblastic leukemia; amL – acute myelogenous leukemia; cGVhD – chronic graft- vs -host disease; CLL – chronic lymphocytic leuke-
mia; CmL – chronic myelogenous leukemia; F – female; Gi – gastrointestinal; m – male; mDS – myelodysplastic syndrome; Nih – National institutes of 
health; PNh – paroxysmal nocturnal hemoglobinuria.
†Fisher exact test or Fisher-Freeman-halton exact test of independence when the contingency table is larger than 2 × 2.
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(P < 0.001) (Table 5). There was no significant association 
in other cGVHD organ involvement (eyes, lungs, gastroin-
testinal tract, liver, mouth, genitalia in female patients) be-
tween these two groups (Table 5).
Among categorical outcomes, there was no significant 
association between donor sex, main disease, stem cell 
source, relationship of donor to patient (related or unre-
lated), sex mismatch of HSCT, myeloablative conditioning, 
TabLE 3. Differences in quantitative clinical characteristics of groups with cGVhD*
Joint/fascia cGVhD absent N = 17 Joint/fascia cGVhD present N = 12
25th percentile median 75th percentile 25th percentile median 75th percentile P†
2- minute walk test 189.50 201.00 211.50 146.75 188.00 202.00 0.097
HGS-D 40.00 46.60 67.45 34.88 48.30 64.98 0.842
HGS-ND 36.95 46.60 53.30 35.50 45.00 60.00 0.859
P-ROM scale 25.00 25.00 25.00 18.50 22.00 22.75 <0.001
NIH total score 3.00 4.00 4.00 4.50 6.50 8.75 0.002
Number of involved organs 2.00 2.00 3.00 3.00 4.00 6.00 0.006
Age at entry 26.00 37.00 52.00 26.25 44.50 56.75 0.565
Days from transplant to enrolment 263.50 574.00 3052.50 343.50 843.00 3986.50 0.364
Days from cGVHD Dx to enrolment 28.25 153.50 452.75 80.00 492.00 3393.25 0.131
Karnofsky/Lansky score 90.00 100.00 100.00 62.50 80.00 87.50 <0.001
*cGVhD – chronic graft-vs-host disease; hGS-D/hGS-ND – hand grip strength (dominant and non-dominant hand); Nih – National institutes of 
health; P-Rom – photographic range of motion scale.
†mann-Whitney u test.
TabLE 4. Correlations between Nih joint/fascia score and significant variables in the group of cGVhD patients: Spearman correlation 
coefficients (n = 29)*
Nih joint/fascia score
P-ROM Correlation coefficient -0.989
P <0.001
2- minute walk test Correlation coefficient -0.444
P 0.016
NIH score skin Correlation coefficient 0.712
P <0.001
NIH total score Correlation coefficient 0.603
P 0.001
Number of organs involved with cGVHD Correlation coefficient 0.452
P 0.014
Karnofsky/Lansky score Correlation coefficient -0.759
P <0.001
Cytotoxic T cells (CD3+/CD8+) (%) Correlation coefficient -0.456
P 0.022
Cytotoxic T cells (CD3+/CD8+) (number of cells) Correlation coefficient -0.378
P 0.062
CK Correlation coefficient -0.462
P 0.012
WBC Correlation coefficient 0.406
P 0.032
C3 comp Correlation coefficient 0.405
P 0.045
Albumin Correlation coefficient -0.402
P 0.047
*C3 – complement component 3; cGVhD – chronic graft-vs-host disease; CK – creatine kinase; Nih – National institutes of health; P-Rom– photo-
graphic range of motion scale; WbC– white blood count.
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history of acute cGVHD, greater intensity of immunosup-
pressive therapy at time of evaluation with joint and fascial 
cGVHD (Table 2).
Patients with joint and fascial cGVHD had significantly low-
er Karnofsky score (P < 0.001), lower P-ROM scale (P < 0.001), 
higher NIH total score (P = 0.002) (Table 3) and lower per-
centage of cytotoxic T cells CD3+/CD8+ (P = 0.017) and cy-
totoxic T cells CD3+/CD8+ count (P = 0.037) than patients 
without joint and fascial cGVHD (Supplementary Table 1).
There was no significant difference between two groups of 
patients in patients age, longer time from transplant to en-
rolment in the study, longer time from diagnosis of cGVHD 
to enrolment in the study, number of organs involved with 
cGVHD, HGS (dominant and non-dominant hand) (Table 
3), laboratory parameters (CRP, platelet count, red blood 
count, white blood count, lymphocyte count, absolute 
neutrophil, eosinophil, basophil and lymphocyte subset 
counts (CD4 T-cell, CD8 T-cell, B-cell, natural killer cell), he-
moglobin, C3 and C4 complement component, IgA, IgM, 
IgG, total proteins, erythrocyte sedimentation rate, ferritin, 
β2 microglobulin, positive antinuclear antibodies (ANAs), 
rheumatoid factor, cardiolipin antibodies IgM, cardiolipin 
antibodies IgG titers and patients who had joint and fascial 
cGVHD (Supplementary Table 1).
Logistic regression predictive models of cGVhD joint/
fascia compared with other organ systems
To determine which organ involvement is the most predic-
tive factor for the development of joint and fascial cGVHD, 
a binary logistic regression model was used. NIH joint/fas-
cia score was compared with that of other organ systems; 
with exception of the genital tract, which was excluded 
because these data were available only for female patients. 
This model showed that cGVHD skin involvement was a 
significant predictor (odds ratio, 7.79; 95 confidence in-
terval, 1.87-32.56; P = 0.005) of cGVHD joint/fascia involve-
ment, controlled for all other variables included in regres-
sion model (Table 6). Regression model was statistically 
significant (P = 0.007) with 65.7% of dependent variable 
(positive cGVHD joint/fascia involvement) explained. Hos-
mer-Lemeshow goodness of fit test result for this regres-
sion model was not significant (P = 0.542), supporting the 
regression model.
DiSCuSSioN
This study showed a 41.3% incidence of joint and fascial 
manifestations in patients with cGVHD and a strong cor-
relation of joint and fascial cGVHD with skin cGVHD, which 
was also found in some other studies (9,11,23). Joint/fas-
cia manifestations are significantly associated with skin 






Nih score N % N % P†
Genital tract 
(women only)
0 5 50.0 2 50.0 1.000
1 1 10.0 1 25.0
3 4 40.0 1 25.0
Lung 0 8 47.1 3 30.0 0.867
1 5 29.4 5 50.0
2 2 11.8 1 10.0
3 2 11.8 1 10.0
Liver 0 12 70.6 7 63.6 0.894
1 2 11.8 3 27.3
2 2 11.8 1  9.1
3 1 5.9 0  0.0
GI tract 0 15 88.2 11 91.7 1.000
1 2 11.8 1  8.3
Eyes 0 7 41.2 5 41.7 0.202
1 9 52.9 3 25.0
2 1 5.9 2 16.7
3 0 0.0 2 16.7
Mouth 0 12 70.6 6 54.5 0.686
1 1 5.9 2 18.2
2 3 17.6 3 27.3
3 1 5.9 0  0.0
Skin 0 13 76.5 2 16.7 <0.001
1 3 17.6 2 16.7
2 1 5.9 3 25.0
3 0 0.0 5 41.7
*cGVhD – chronic graft-vs-host disease; Gi – gastrointestinal; Nih – 
National institutes of health.
†Fisher exact test or Fisher-Freeman-halton exact test of indepen-
dence when the contingency table is larger than 2 × 2.
TabLE 6. Predictive models for cGVhD of joint/fascia using Nih 
scoring system: binary logistic regression*
95% confidence interval
Nih score odds ratio lower upper P
Skin 7.80 1.87 32.56 0.005
Lung 1.34 0.31 5.72 0.692
Liver 0.24 0.03 1.92 0.179
GI tract 0.05 0.00 3.15 0.158
Eyes 0.89 0.13 5.95 0.902
Mouth 3.78 0.55 26.20 0.178
*cGVhD – chronic graft-vs-host disease Gi – gastrointestinal; Nih– 
National institutes of health.
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cGVHD changes, particularly superficial/erythematous and 
deep skin sclerosis. Patients in this study who were graded 
as having a severe (N = 3, 25%) NIH joint/fascia score were 
the only ones with deep skin sclerosis. Upper extremi-
ties were more affected with ROM reduction in our study 
group than lower extremities, consistent with other stud-
ies (6,23).Two patients from JFS group had isolated joint 
involvement (N = 2, 16.7%) without any skin manifestation 
of cGVHD with both patients graded as having mild NIH 
joint/fascia score. This percentage is low and consistent 
with other studies that suggest that isolated joint involve-
ment in cGVHD is fairly uncommon (8).
Since these patients have a high risk for functional impair-
ment, valid and practical methods are needed for assess-
ing functional capacity measures. We found that joint and 
fascial cGVHD correlated with a worse score on the 2-min-
ute walk test, but not with HGS. This supports findings of 
some previous studies. One study found an association of 
2- minute walk test and cGVHD severity and mortality, al-
though the test was not sensitive to cGVHD response and 
there was no association of change in 2-minute walk test 
with subsequent mortality (24). Our data do not support 
the use of the HGS as a measurement in joint and fascial 
cGVHD patients (15,24), The 2014 NIH Consensus Devel-
opment Project for cGVHD also recommended that HGS 
should not be included in routine patient assessment (25). 
We also found no association between joint and fascial 
cGVHD and HGS, although joint contractures and muscle 
weakness confound the measurement of HGS (26).
This study also identified that some laboratory indica-
tors of inflammation (white blood count, cytotoxic T cells 
CD3+/CD8+, and albumin) correlated with joint and fascial 
cGVHD, suggesting increased inflammation in this patient 
population (27). This was also the case in some other stud-
ies, which identified even more inflammatory parameters 
to be associated with cGVHD (9,11).
This study found a correlation between lower cytotoxic T 
cell CD3+/CD8+ percentage and joint and fascial cGVHD. 
The reason for this is unclear, but could be the presence of 
a lower proportion of cytotoxic T cells in the blood, as cy-
totoxic T cells have been shown to relocate into organs af-
fected with cGVHD (27). This explanation assumes on-go-
ing tissue inflammation in this patient population.
In our patients, joint and fascial cGVHD correlated with el-
evated serum C3 complement. This is similar to other stud-
ies, in which higher C3 levels were associated with most se-
vere joint and fascia involvement and skin (sclerotic type) 
changes in patients with cGVHD (9,11). Elevated serum C3 
complement was also found in glomerular membranes in 
patients with cGVHD and nephrotic syndrome (28,29), and 
deposits of C3 were found at the dermal-epidermal junc-
tion in skin biopsies of patients with cGVHD (30,31) and 
with systemic sclerosis (32).
cGVHD characteristics were also compared between pa-
tients with and without joint and fascial manifestations 
at enrolment. Joint and fascia manifestations were signif-
icantly associated with more frequent skin involvement 
but not with other organ involvement (eyes, lungs, liver, 
GI tract, mouth, genitalia in female patients). As NIH total 
score was higher, and as Karnofsky score decreased, there 
was a higher possibility that cGVHD would also manifest as 
joint/fascia involvement.
There was also a significant association between lower 
creatine kinase (CK) levels and joint/fascial cGVHD involve-
ment in our study, which may be due to multiple factors, 
including muscle breakdown from decreased physical ac-
tivity, increased prednisone use due to disease severity, 
and as a general indicator for inflammation.
Acute GVHD is an established risk factor for the develop-
ment of cGVHD (5,15,33), however our study found no cor-
relation between acute GVHD and cGVHD joint involve-
ment. Research that explored skin changes has also not 
found any significant association between predominantly 
sclerotic skin changes and acute cGVHD (9,11).
Other potential risk factors considered when examining pa-
tients with cGVHD, including use of high-dose total body 
irradiation conditioning, longer duration from transplanta-
tion to enrolment and prevalent cases, were not found to 
be associated with cGVHD joint/fascia involvement in our 
patients. This a potential weakness of the study, as other 
studies have found significant association between this 
parameters and cGVHD joint/fascia manifestations (6,8).
In the interpretation of our study results, several limita-
tions must be considered. The sample size was relatively 
small, limiting the statistical analysis with numerous vari-
ables, so further investigations with a larger sample size 
should be considered. Furthermore, patients were only 
evaluated at one time point, so monitoring of these pa-
tients for symptom progression or regression was not 
possible. Therefore, we cannot conclude that the ob-
served relationships are solely the result of cGVHD. 
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Furthermore, it is unclear if some of the functional impair-
ment are a result of cGVHD treatment– often prednisone, 
which can cause debilitating myopathy and orthopedic 
complications (34) or of the disease process itself. Howev-
er, such in-depth multifaceted studies of cGVHD patients 
are exceptionally rare.
This study did, however, show a correlation between spe-
cific laboratory findings and clinical features with joint and 
fascial cGVHD. Therefore, we believe that it fills an impor-
tant gap in the knowledge about disabling joint and fascial 
involvement in patients who have developed cGVHD after 
alloHSCT. AlloHSCT recipients should be carefully moni-
tored in order to identify patients at an earliest stage of the 
disease and ensure successful therapy interventions. .
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